Elutia INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ELUT
Elutia INCElutia Inc. reported a net income of $53.38 million for 2025, driven by the strategic divestiture of its CIED business, while focusing on next-generation drug-eluting biomatrix products.
NASDAQ
ELUT
Elutia INCElutia Inc.'s 2024 10-K filing reveals a year of strategic transition, marked by the sale of its Orthobiologics Business, FDA clearance for EluPro, ongoing litigation, and efforts to manage liquidity and future growth.
NASDAQ
ELUT
Elutia INC10-K: Elutia Inc. 2023 Annual Report: Strategic Shift and Focus on Device Protection and Women's Health
Elutia Inc.'s 2023 annual report highlights a strategic shift following the sale of its Orthobiologics business, focusing on device protection and women's health markets while navigating challenges from product recalls and litigation.